An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE)

被引：8
|
作者：
Machiels, J. H.
Subramanian, S.
Ruzsa, A.
Repassy, G.
Lifrenko, I.
Flygare, A.
Sorensen, P.
Ehrnrooth, E.
Baadsgaard, O.
Clement, P. M.
机构：
[1] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium
[2] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[3] Zala Megyei Korhaz, Onkol Osztaly, Zalaegerszeg Pozva, Hungary
[4] Semmelweis Univ, H-1085 Budapest, Hungary
[5] Kursk Reg Oncol Dispencary, Kursk, Russia
[6] Genmab, Copenhagen, Denmark
[7] Univ Hosp Leuven, Dept Gen Med Oncol, Louvain, Belgium
[8] Catholic Univ Louvain, B-3000 Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 18期
关键词：
D O I：
10.1200/jco.2010.28.18_suppl.lba5506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5506
引用
收藏
页数：1
相关论文
共 27 条
  • [1] Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
    Machiels, Jean-Pascal
    Subramanian, Somasundaram
    Ruzsa, Agnes
    Repassy, Gabor
    Lifirenko, Igor
    Flygare, Annika
    Sorensen, Per
    Nielsen, Tina
    Lisby, Steen
    Clement, Paul M. J.
    LANCET ONCOLOGY, 2011, 12 (04): : 333 - 343
  • [2] An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
    Saloura, Vassiliki
    Cohen, Ezra E. W.
    Licitra, Lisa F.
    Billan, Salem
    Dinis, Jose
    Lisby, Steen
    Gauler, Thomas Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
    Vassiliki Saloura
    Ezra E. W. Cohen
    Lisa Licitra
    Salem Billan
    Jose Dinis
    Steen Lisby
    Thomas C. Gauler
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1227 - 1239
  • [4] An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
    Saloura, Vassiliki
    Cohen, Ezra E. W.
    Licitra, Lisa
    Billan, Salem
    Dinis, Jose
    Lisby, Steen
    Gauler, Thomas C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1227 - 1239
  • [5] AN OPEN-LABEL, PHASE I/II DOSE-ESCALATION TRIAL INVESTIGATING ZALUTUMUMAB, A HUMAN MONOCLONAL EGF RECEPTOR (EGFR) ANTIBODY. IN COMBINATION WITH CHEMO-RADIATION AS FIRST LINE TREATMENT OF PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Gregoire, V.
    Maingon, P.
    Nuyls, S.
    Calais, G.
    Gross, N.
    Thelin, U.
    Sorensen, P.
    Nielsen, T.
    Brun, E.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S309 - S310
  • [6] Triple oral metronomic chemotherapy (OMCT) versus physician choice chemotherapy after failure of platinum-based therapy in advanced head and neck squamous cell cancer (HNSCC): A phase III randomized open-label study
    Kapoor, A.
    Gupta, A.
    Sansar, B.
    Singh, A.
    Kashyap, L.
    Kumari, R.
    Kumar, A.
    Nanda, S.
    Kapoor, A. R.
    Mukherji, A.
    Mishra, A.
    Pal, A.
    Bandekar, B.
    Singh, S. N.
    Vinayak, K.
    Dey, S.
    Patil, V. M.
    Noronha, V.
    Banavali, S.
    Prabhash, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S589 - S589
  • [7] Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
    Bellmunt, J.
    Fougeray, R.
    Rosenberg, J. E.
    von der Maase, H.
    Schutz, F. A.
    Salhi, Y.
    Culine, S.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1466 - 1472
  • [8] Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
    Vermorken, Jan B.
    Trigo, Jose
    Hitt, Ricardo
    Koralewski, Piotr
    Diaz-Rubio, Eduardo
    Rolland, Frederic
    Knecht, Rainald
    Amellal, Nadia
    Schueler, Armin
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) : 2171 - 2177
  • [9] Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial
    Guo, Y.
    Ahn, M-J
    Chan, A.
    Wang, C-H
    Kang, J-H
    Kim, S-B
    Bello, M.
    Arora, R. S.
    Zhang, Q.
    He, X.
    Li, P.
    Dechaphunkul, A.
    Kumar, V
    Kamble, K.
    Li, W.
    Kandil, A.
    Cohen, E. E. W.
    Geng, Y.
    Zografos, E.
    Tang, P. Z.
    ANNALS OF ONCOLOGY, 2019, 30 (11) : 1831 - 1839
  • [10] Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
    Baselga, J
    Trigo, JM
    Bourhis, J
    Tortochaux, J
    Cortés-Funes, H
    Hitt, R
    Gascón, P
    Arnellal, N
    Harstrick, A
    Eckardt, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5568 - 5577
123